NephroGenex to Present at BioEquity Europe 2014 Conference

NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Pierre Legault, Chief Executive Officer, will present a corporate overview at the 15th annual BioEquity Europe conference at the Hilton Amsterdam Hotel in Amsterdam.

Mr. Legault will present from 3:20 – 3:40 PM CEST on Thursday, May 22, 2014 in Ballroom C.

Pyridorin is the Company’s product candidate for the treatment of diabetic nephropathy—a chronic, degenerative disease of the kidney for which there are few therapeutic options. NephroGenex received Fast Track designation and a Special Protocol Assessment from FDA for Pyridorin, and is preparing to launch its pivotal, Phase 3 trial in patients with diabetic nephropathy in the next several months.

BioEquity Europe is an industry-sponsored event for financial dealmakers and investor-validated life science companies.

About NephroGenex, Inc.

NephroGenex (Nasdaq:NRX) is a clinical-stage pharmaceutical company focused on developing therapeutics to treat kidney diseases caused by pathogenic oxidative chemistries. Since our inception, we have collaborated with the leading scientific experts in pathogenic oxidative chemistries to build a strong portfolio of intellectual property and novel acting drug candidates. Our clinical program has been done in collaboration with world leading clinical investigators in kidney disease. Our product pipeline includes an oral formulation of Pyridorin, which is being developed as a chronic, therapeutic agent to slow the progression of diabetic nephropathy, as well as an intravenous formulation of Pyridorin to treat specific types of acute kidney injury.

Cautionary Note on Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will,” or words of similar meaning and include, but are not limited to, statements regarding the outlook for our future business and financial performance. Forward-looking statements are based on management’s current expectations and assumptions, which are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Actual outcomes and results may differ materially due to global political, economic, business, competitive, market, regulatory and other factors and risks, including the items identified under “Part I—Item 1A—Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2013, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2014, as well as in other filings that we may make with the SEC in the future. The forward-looking statements contained in this press release reflect our current views with respect to future events, and we do not undertake and specifically disclaim any obligation to update any forward-looking statements.